<DOC>
	<DOC>NCT00630539</DOC>
	<brief_summary>The purpose of the study is to assess the efficacy, safety and tolerability of Ospemifene 5 mg, 15 mg, and 30 mg in the treatment of VVA in postmenopausal women to find the minimum effective dose below the lowest dose of 30 mg tested earlier in Phase II.</brief_summary>
	<brief_title>A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Naturally or surgically menopausal Vaginal pH greater than 5.0 5% or fewer superficial cells in maturation index of vaginal smear Evidence of endometrial hyperplasia, cancer or other pathology Abnormal PAP smear Uterine bleeding of unknown origin or uterine polyps Current vaginal infection requiring medication Use of hormonal medications Clinically significant abnormal gynecological findings other than signs of vaginal atrophy</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Menopausal symptoms</keyword>
	<keyword>Urogenital atrophy</keyword>
	<keyword>Vulvar and vaginal atrophy in postmenopausal women</keyword>
	<keyword>Vaginal atrophy</keyword>
</DOC>